Chronic Inflammation and the Role for Cofactors (hepatitis C, Drug Abuse, Antiretroviral Drug Toxicity, Aging) in HAND Persistence

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2014 Jun 16

PMID 24929842

Citations 37

Authors

Alexander J Gill

Dennis L Kolson

Affiliations

Soon will be listed here.

Abstract

HIV-associated neurocognitive disorders (HAND) is a group of syndromes of varying degrees of cognitive impairment affecting up to 50 % of HIV-infected individuals. The neuropathogenesis of HAND is thought to be driven by HIV invasion and productive replication within brain perivascular macrophages and endogenous microglia, and to some degree by restricted infection of astrocytes. The persistence of HAND in individuals experiencing suppression of systemic HIV viral load with antiretroviral therapy (ART) is incompletely explained, and suggested factors include chronic inflammation, persistent HIV replication in brain macrophages, effects of aging on brain vulnerability, and co-morbid conditions including hepatitis C (HCV) co-infection, substance abuse, and CNS toxicity of ART, among other factors. This review discusses several of these conditions: chronic inflammation, co-infection with HCV, drugs of abuse, aging, and antiretroviral drug effects. Effectively managing these co-morbid conditions in individuals with and without HAND is critical for improving neurocognitive outcomes and decreasing HIV-associated morbidity.

Citing Articles

HIV-Associated Neurocognitive Disorder: A Look into Cellular and Molecular Pathology.

Thompson L, Genovese J, Hong Z, Singh M, Singh V Int J Mol Sci. 2024; 25(9).

PMID: 38731913 PMC: 11083163. DOI: 10.3390/ijms25094697.

Human iPSC-derived neurons reveal NMDAR-independent dysfunction following HIV-associated insults.

Starr A, Nickoloff-Bybel E, Abedalthaqafi R, Albloushi N, Jordan-Sciutto K Front Mol Neurosci. 2024; 16:1353562.

PMID: 38348237 PMC: 10859444. DOI: 10.3389/fnmol.2023.1353562.

Lipid nanocarrier targeting activated macrophages for antiretroviral therapy of HIV reservoir.

Wu D, Si M, Xue H, Tran N, Khalili K, Kaminski R Nanomedicine (Lond). 2023; 18(20):1343-1360.

PMID: 37815117 PMC: 10652294. DOI: 10.2217/nnm-2023-0120.

Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND).

Kolson D Curr HIV/AIDS Rep. 2022; 19(5):344-357.

PMID: 35867211 PMC: 9305687. DOI: 10.1007/s11904-022-00612-2.

Advances in SIV/SHIV Non-Human Primate Models of NeuroAIDS.

Moretti S, Virtuoso S, Sernicola L, Farcomeni S, Maggiorella M, Borsetti A Pathogens. 2021; 10(8).

PMID: 34451482 PMC: 8398602. DOI: 10.3390/pathogens10081018.

References

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

Gaskill P, Calderon T, Coley J, Berman J . Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND. J Neuroimmune Pharmacol. 2013; 8(3):621-42. PMC: 4303241. DOI: 10.1007/s11481-013-9443-y. View

Czub S, Czub M, Koutsilieri E, Sopper S, Villinger F, Muller J . Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. Acta Neuropathol. 2004; 107(3):216-26. DOI: 10.1007/s00401-003-0801-3. View

Douek D . Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev. 2003; 5(3):172-7. View

Dave R, Khalili K . Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system. J Cell Biochem. 2010; 110(4):834-45. PMC: 2923828. DOI: 10.1002/jcb.22592. View

Robertson K, Su Z, Margolis D, Krambrink A, Havlir D, Evans S . Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010; 74(16):1260-6. PMC: 2860482. DOI: 10.1212/WNL.0b013e3181d9ed09. View

. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372(9635):293-9. PMC: 3130543. DOI: 10.1016/S0140-6736(08)61113-7. View

Perez-Valero I, Gonzalez-Baeza A, Estebanez M, Montes-Ramirez M, Bayon C, Pulido F . Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One. 2013; 8(7):e69493. PMC: 3723908. DOI: 10.1371/journal.pone.0069493. View

Martins T, Baptista S, Goncalves J, Leal E, Milhazes N, Borges F . Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res. 2011; 1411:28-40. DOI: 10.1016/j.brainres.2011.07.013. View

10.

Heaton R, Franklin D, Ellis R, McCutchan J, Letendre S, LeBlanc S . HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2010; 17(1):3-16. PMC: 3032197. DOI: 10.1007/s13365-010-0006-1. View

11.

Clifford D, Evans S, Yang Y, Gulick R . The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS. 2005; 19 Suppl 3:S64-71. DOI: 10.1097/01.aids.0000192072.80572.43. View

12.

Banerjee A, Strazza M, Wigdahl B, Pirrone V, Meucci O, Nonnemacher M . Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol. 2011; 17(4):291-302. PMC: 3757547. DOI: 10.1007/s13365-011-0037-2. View

13.

Marra C, Zhao Y, Clifford D, Letendre S, Evans S, Henry K . Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009; 23(11):1359-66. PMC: 2706549. DOI: 10.1097/QAD.0b013e32832c4152. View

14.

Wallet M, Rodriguez C, Yin L, Saporta S, Chinratanapisit S, Hou W . Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS. 2010; 24(9):1281-90. PMC: 2888494. DOI: 10.1097/QAD.0b013e328339e228. View

15.

Anthony I, Ramage S, Carnie F, Simmonds P, Bell J . Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol. 2006; 111(6):529-38. DOI: 10.1007/s00401-006-0037-0. View

16.

Xu J, Ikezu T . The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol. 2008; 4(2):200-12. PMC: 2682636. DOI: 10.1007/s11481-008-9136-0. View

17.

Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. PMC: 4472366. DOI: 10.1212/01.WNL.0000287431.88658.8b. View

18.

Burdo T, Lo J, Abbara S, Wei J, DeLelys M, Preffer F . Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011; 204(8):1227-36. PMC: 3203384. DOI: 10.1093/infdis/jir520. View

19.

Neaton J, Neuhaus J, Emery S . Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS. 2010; 5(6):480-90. PMC: 3079321. DOI: 10.1097/COH.0b013e32833ed75d. View

20.

Seider T, Luo X, Gongvatana A, Devlin K, de la Monte S, Chasman J . Verbal memory declines more rapidly with age in HIV infected versus uninfected adults. J Clin Exp Neuropsychol. 2014; 36(4):356-67. PMC: 4317358. DOI: 10.1080/13803395.2014.892061. View